The clinical significance of lymphangiogenesis in renal cell carcinoma

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 606-611

  Debiński, Paweł ^a   Dembowski, Janusz ^a   Kowal, Paweł ^a   Szydełko, Tomasz ^a   Kołodziej, Anna ^a   Małkiewicz, Bartosz ^a   Tupikowski, Krzysztof ^a   Zdrojowy, Romuald ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Immunohistochemistry; Lymphangiogenesis; Lymphatic vessels; Prognosis; Renal cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISTANT METASTASIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LYMPH NODE; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; POLAND; SURVIVAL RATE;

EID: 84880748134     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883981     Document Type: Article

References (22)

1. Campbell SC, Novick AC, Bukowski RM: Renal tumors. In Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CP. Campbell-Walsh Urology, 9th edn, Philadelphia: Saunders Elsevier, 2007; Chapt. 47; 1582-1632
2. Achen MG, Mann GB, Stacker SA: Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer, 2006; 22: 1355-60
3. Schips L, Dalpiaz O, Lipsky K et al: Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol, 2007; 51: 168-74
4. Minardi D, Lucarini G, Mazzucchelli R et al: Prognostic role of Fuhrman grade and vascular endothelial growth factor in pt1a clear cell carcinoma in partial nephrectomy specimens. J Urol, 2005; 174: 1208-12
5. Rivet J, Mourah S, Murata H et al: VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer, 2008; 112(2): 433-42
6. Partyka R, Gonciarz M, Jałowiecki P et al: VEGF and metalloproteinase 2 (MMP2) expression in gastric cancer tissue. Med Sci Monit, 2012; 18(4): BR130-34
7. Saad RS, Kordunsky L, Liu YL et al: Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol, 2006; 19: 1317-23
8. Miyata Y, Kanda S, Ohba K et al: Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract-association with clinicopathological features and prognosis. J Urol, 2006; 176: 348-53
9. Skobe M, Hawighorst T, Jackson DG et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med, 2001; 7: 192-98
10. Andree C, Schmidt VJ, Munder BIJ et al: Detecting of breast cancer metastasis by means of regional lymph node sampling during autologous breast reconstruction-a screening of 519 consecutive patients. Med Sci Monit, 2012; 18(10): CR605-10
11. Kahn HJ, Marks A: A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest, 2002; 82(9): 1255
12. Kaiserling E: Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology. Pathologe, 2004; 25: 362-74
13. Van der Auwera I, Cao Y, Tille JC et al: First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer, 2006; 95(12): 1611-25
14. Horiguchi A, Ito K, Sumitomo M et al: Intratumoral lymphatics and lymphatic invasion are associated with tumor aggressiveness and poor prognosis in renal cell carcinoma. Urology, 2008; 71(5): 928-32
15. Iwata T, Miyata Y, Kanda S et al: Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma-association with vascular endothelial growth factors A to D immunohistochemistry. Urology, 2008; 71(4): 749-54
16. Breiteneder-Geleff S, Soleiman A, Kowalski H et al: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol, 1999; 154: 385-94
17. Jackson DG, Prevo R, Clasper S, Banerji S: LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol, 2001; 22: 317-21
18. Kaipainen A, Korhonen J, Mustonen T et al: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA, 1995; 92: 3566-70
19. Trojan L, Rensch F, Voss M et al: The role of the lymphatic system and its specific growth factor vascular endothelial growth factor C for lymphogenic metastasis in prostate cancer. BJU Int, 2006; 98: 903-6
20. Padera TP, Kadambi A, di Tomaso E et al: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 2002; 296(5574): 1883-86
21. Baldewijns MM, Roskams T, Ballet V et al: A low frequency of lymph node metastasis in clear-cell renal carcfinoma is related to low lymphangiogenic activity. BJU Int, 2009; 103(12): 1626-31
22. Voss M, Steidler A, Grobholz R et al: The lymphatic system and its specific growth factor vascular endothelial growth factor C in kidney tissue and in renal cell carcinoma. BJU Int, 2009; 104(1): 94-99